IPO
Auris Medical Holding Ltd. announced today the closing of its previously announced underwritten public offering
GeoVax Labs, Inc. announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings
Auris Medical Holding Ltd. announced the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares.
Funding to scale-up company’s proprietary technology C-Stem™ for mass-production of safe and affordable cell therapies
MyoKardia, Inc. reported financial results for the quarter ended March 31, 2019.
Neos Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided a business update.
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.
PRESS RELEASES